OTCMKTS:PDDPF Medexus Pharmaceuticals (PDDPF) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free PDDPF Stock Alerts $2.14 0.00 (0.00%) (As of 08/4/2023) Add Compare Share Share Today's Range$2.11▼$2.4250-Day Range$2.14▼$2.1452-Week Range$1.70▼$3.99Volume39,966 shsAverage Volume4,355 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesStock AnalysisHeadlines Get Medexus Pharmaceuticals alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Medexus Pharmaceuticals Stock (OTCMKTS:PDDPF)Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company. It provide healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease and pediatrics. The company products include Rasuvo, Metoject and Rupall. Medexus was founded by Sylvain Chretien in January 2008 and is headquartered in Verdun, Canada.Read More PDDPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PDDPF Stock News HeadlinesApril 3, 2024 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc flat on Monday (MDP)January 10, 2024 | morningstar.comMedexus Pharmaceuticals Inc MEDXFApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. December 21, 2023 | morningstar.comMedexus Pharmaceuticals Inc MDPNovember 1, 2023 | msn.comMedexus Pharmaceuticals (MEDXF) Price Target Increased by 8.29% to 3.16October 18, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc flat on Tuesday (MDP)October 17, 2023 | finance.yahoo.comMedexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public OfferingOctober 13, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc 6.0 Pct Debs flat on Wednesday (MDP-DB)April 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. October 11, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc 6.0 Pct Debs flat on Friday (MDP-DB)September 6, 2023 | msn.comMedexus Pharmaceuticals announces C$10M offeringAugust 4, 2023 | finance.yahoo.comMedexus to Participate in Fireside Chat at SHARE Series EventJune 22, 2023 | markets.businessinsider.comStifel Nicolaus Upgrades Medexus Pharmaceuticals Inc (MDP) to BuyJune 20, 2023 | finance.yahoo.comMorning News Call - Canada, June 20May 16, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc down on Monday (MDP)May 10, 2023 | msn.comMedexus gets TSX nod to make NCIB for convertible debenturesMay 9, 2023 | marketwatch.comPharmaceutical Drug Delivery Market Research Findings to 2030April 22, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc down on Friday (MDP)April 11, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc up on Monday (MDP)April 11, 2023 | marketwatch.comMedexus Pharma Names Michael Mueller Chairman, Forecasts Rise in 4Q RevenueApril 11, 2023 | msn.comMedexus expects FY23 record revenue of $107M-$108MMarch 20, 2023 | marketwatch.comDiaphragm Valves for Pharmaceutical Process Market 2023 Key Product Segments, Application Analysis, and Industry Growth Forecast by 2029February 22, 2023 | marketwatch.comDrug and Pharmaceuticals and Cosmetics Retail Market Foreseen To Grow Exponentially Over 2023-2029February 2, 2023 | marketwatch.comAn Overview of Anti-Counterfeit Pharmaceuticals And Cosmetics Market, Major Participants, and Prospects by 2029January 31, 2023 | marketwatch.comMiddle-aged and Elderly Health Supplements Market: 2023 [Latest Report] By Top Leading Players Analysis Till 2028January 31, 2023 | marketwatch.comOral Mucositis Market with Strong Focus on Industry Size, by Financial Highlights, Market Segments, Growth Rate, Revenue, and Forecast to 2029January 30, 2023 | marketwatch.comPeptide Therapy Industry by 360 Market Updates with, New Companies, Major Strategies, Massive Strategies And Forecast 2028See More Headlines Receive PDDPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:PDDPF CUSIPN/A CIKN/A Webwww.medexus.com Phone(514) 762-2626FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesKenneth d’EntremontChief Executive Officer & DirectorRoland BoivinChief Financial OfficerMichael PineSenior VP-Business Development & StrategyRichard LabelleVice President-Marketing & SalesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors PDDPF Stock Analysis - Frequently Asked Questions How have PDDPF shares performed in 2024? Medexus Pharmaceuticals' stock was trading at $2.14 at the beginning of the year. Since then, PDDPF shares have increased by 0.0% and is now trading at $2.14. View the best growth stocks for 2024 here. How do I buy shares of Medexus Pharmaceuticals? Shares of PDDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PDDPF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
